Breaking News: Hevolution Foundation Secures $30.7 Million in Series A Funding to Drive Geroscience Research and Aging Therapeutics Innovation

Hevolution Foundation is thrilled to announce a significant funding milestone, having successfully raised an impressive $30.7 million in its latest round of investment. Founded on the principle that every individual deserves the opportunity to live a longer and healthier life, Hevolution serves as a global catalyst and partner dedicated to transforming our understanding of aging and extending healthy human lifespan. This funding will play a pivotal role in advancing Hevolution’s mission to treat aging as a viable target for intervention and to enhance the development of aging-related therapeutics. With a focus on accelerating drug development timelines and increasing accessibility to effective treatments, Hevolution aims to support a wide array of research initiatives that address aging processes. Based in Riyadh with a North American hub, the organization is already the second largest funder in the field of geroscience, boasting an annual budget that could reach up to $1 billion. This new capital infusion will bolster their plans to open additional offices globally, cultivating a dynamic ecosystem of leading researchers and innovators. This strategic expansion is instrumental in Hevolution’s quest to facilitate groundbreaking medical breakthroughs that will enhance the healthspan of populations worldwide. Together, with the support of this funding, Hevolution Foundation is poised to accelerate the pace of scientific discovery in aging and geroscience, ultimately delivering impactful solutions that empower humanity to lead healthier, longer lives.